Apolipoprotein-AII (apo-AlD is one of a family of evolutionarily related proteins which play a crucial role in lipid transport and metabolism. The serum levels of human apo-AII have been shown to be inversely correlated to the incidence of coronary heart disease and its expression to be limited to the liver and intestine. Here we demonstrate that this dual tissue-3pecificity involves DNA sequences located in a 259 bp region centred 782 bp upstream from the transcription initiation site. These sequences function in an orientation-independent manner and are absolutely required for transcription from the apo-AII promoter. The regulatory region contains sequences which are homologous to the apo-AI, B-globin and immunoglobulin gene promoters and to the immunoglobulin heavy-chain enhancer.
INTRODUCTION
There is a growing body of evidence that the tissue specific and developmental regulation of individual genes Is controlled by unique combinations of specific and nonspecific cis and trans-acting elements. While relatively little is known about these latter factors, DNA sequences associated with a number of genes have been identified which are responsible for the control of spatial and temporal transcription. Such elements have been found within the promoter region [1] [2] , within exons [3] , up to 6 Kb upstream of the transcription start site [4] and both 5' and 3' of the translation initiation site [5] , In addition, it has been shown that their action can be either orientation independent [6] [7] [8] or orientation dependent [9] . However, to date, the majority of these cis-acting elements have been identified in higher eukaryotic genes whose expression is limited mainly to a single tissue-type. The apolipoprotein gene family, on the other hand, is transcribed in a range of tissue types [10] [11] [12] [13] [14] and so provides an opportunity to study how restricted but multiple tissue specific expression is controlled.
Knowledge of these regulatory mechanisms is of particular interest given the central role played by the apolipoproteins in lipid transport and metabolism and the intimate association of related defects with the pathogenesis of cardiovascular disease. While apolipoprotein deficiencies have been identified as the cause of a limited number of lipid disorders, it is the combination of several, individually innocuous, genetic defects which probably is the main influence on the etiology of atherosclerosis. The control of apo-AI and apo-AII gene expression is of particular interest since these proteins represent the main structural components of high density lipoprotein (HDL) particles whose plasma concentrations appear to be inversely correlated to the incidence of coronary disease [15] [16] [17] [18] [19] [20] [21] . In this regard, we have previously identified a restriction fragment length polymorphism (RFLP) that links an apparently normal allele of the apo-AI/apo-CIII gene complex with a predisposition to hyperlipidemia and cardiovascular disease [22] [23] . An RFLP linked to the apo-AII gene has also been recently described [24] . This variant associates with apo-AII that, although normal, is present at high circulating levels in the plasma [25] , thus indicating a possible linkage to a regulatory mutant. Detailed knowledge of the elements involved in the regulation of apolipoprotein gene expression are therefore important both in molecular biological and clinical terms.
The human apo-AII gene is transcribed exclusively in the adult liver and intestine [26] [27] [28] [29] [30] and the resulting transcripts appear to be identical [31] .
Our recent demonstration that in 6 to 12 week embryos apo-AII is the only apolipoprotein not expressed in the gut [14] , indicates the expression of this gene is also subject to developmental regulation. A series of experiments was therefore designed to identify those cis-actirtg elements of the human apo-AII gene that may be required for this developmental and tissue-specific expression. Apo-AII gene sequences were linked to the 3' terminal exon of the human al-globin gene and the resulting hybrid constructs introduced into hepatic (Hep-G2 and Hep-3B), intestinal (CaCo-2) and non apo-AII producing (HeLa, DS-1 and EJ138) tissue culture cell lines. These transient expression experiments defined an "enhancer-like" element upstream of the apo-AII gene that directs dual tissue-specific expression.
MATERIALS AND METHODS General Procedures
Purification of DNA, ligation reactions, restriction enzyme digestion, Bal31 digestion, gel electrophoresis, transfer of RNA to nitrocellulose, nick translation and filter hybridization were performed according to established procedures as described by Maniatis et al. [321 Construction of Plasmids All plasmids were constructed and isolated by standard recombinant DNA tecniques [32] using DNA fragments of the human apo-AII gene present In the clone pAIITSM.O [33] . paAII/5'1171.
An EcoRl/HincII fragment covering the apo-AII gene from position -1171 to +1168 was Isolated from plasmid pAIITSJA.O [33] and llgated into pSVotlFd [34] between the StuI and BstEII sites. The correct integration of the insert was tested by a series of analytical restriction enzyme digestions.
paAJI/5'1171 and 912. A Hindlll/HincII fragment, covering the apo-AII gene from position -912 and +1168 was isolated from plasmid pAIITSM.O [33] and ligated between the StuI and BstEII sites of pSValFd [34] . The correct integration of the insert was tested by a series of analytical restriction enzyme digestions. paAII/5'675, 210 and 117.
pAIITSM.O was digested with EcoRl followed by a time course of Bal31 nuclease digestion. The DNA was then digested with Hindi and Inserted between the StuI and BstEII sites of pSValFd [34] . Those recombinants containing apo-AII sequences upstream of the Hindi site were identified by colony hybridization. The orientation of the inserts and the length of apo-AII 5' flanking sequence each recombinant contained was determined by sequencing the plasmid DNA [35, 36] . Three recombinants were finally isolated containing 675, 210 and 117 bp of apo-AII 5 1 [41, 42] cells were grown at 37°C under 5% CO2 in MEM medium supplemented with 10% FCS and 2 mM glutamine. DMEM medium supplemented with 2 mM glutamine and 10% or 20% FCS was used to grow HeLa [43] or CaCo-2 [44] [45] [46] [47] cells respectively. In continuous culture, cells were harvested by trypsinization, seeded at a 1 : 5 dilution and fed with fresh medium every day. All cell lines were grown in 80 cm^ tissue culture flasks (Nunc) and 150 x 15 mm tissue culture dishes (Lux).
DNA Transfection
Hep-G2, Hep-3B, HeLa, CaCo-2, DS-1 and EJ138 cells were transfected with plasmid DNA by the calcium phosphate co-precipitatlon method [A8] with the following modifications: 3 hrs before transfection the cells were fed with fresh medium, 100 \ig of each plasmid was used to transfect two 150 x 15 mm dishes of subconfluent cells. Transfection was for 4 hrs after which the medium was replaced. Preparation of RNA Total cellular RNA was prepared by lysis of cells in 5 M guanadinium isothiocyanate, 50 mM Tris-HCl, pH 7.6, 10 mM EDTA, 0.1 M 8-mercaptoethanol [49] . RNA was pelleted through a cushion of 5.7 M CsCl, 0.1 M EDTA in a Beckman SW50 rotor at 28,000 rpm and 20°C for 24 hrs [50,511 RNA pellets were resuspended in sterile distilled water containing 10 mM rlbonucleoside-vanadyl complex (Biolabs), ethanol precipitated and stored as aqueous solutions at -20°C.
RESULTS
Determination of the approximate 5' border of an element involved in the tissuespecific expression of the apo-AII gene
The majority of the cis-acting regulatory elements which have been implicated in tissue-specific expression are located either within the transcribed portion of the gene they control or in its 5' flanking sequence. Therefore, as the starting point of our search for equivalent control regions associated with apo-AII gene expression, we used a 2339 bp restriction fragment which stretched from 1171 bp upstream of the apo-AII CAP site [31] to within 163 bp of the polyadenylation point.
The construction of the plasmids used to determine the approximate 5' boundary of sequences involved in the direction of the tissue-specific expression of the apo-AII gene is described in Figure 1 . Each construct represents a hybrid gene containing almost the entire transcribed region of the apo-AII gene, lacking only the last 163 bp of the 3' terminal exon (An E4) containing the polyadenylation signal. This signal is replaced with its equivalent from the human ctl-globln gene by the fusion of the remaining 5 1 portion of AH E4 to 218 bp representing the 3' portion of the 3' terminal exon of al-globin (al E3). Therefore, the resulting 3' terminal exon (All E4/ol D) of the hybrid gene only contains sequences that had themselves originally been part of such exons. Consequently the possibility of the mRNA transcribed from the hybrid gene being unstable due to the presence of incompatible and inappropriate exon sequences is minimized. 
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A series of hybrid gene constructs was generated, differing only in the length of apo-AIl gene 5' flanking sequence they contained. Five recombinant plasmids were made: paAII/5'1171, 912, 675, 210 and 117 containing respectively 1171, 912, 675, 210 and 117 bp of apo-AII gene sequence upstream of the transcription initiation site. The SV40 origin and enhancer sequences present in the parent plasmid vector pSValFd (pSVOaip3d in Mellon et al [34] ) were eliminated during the production of these constructs (see Fig.l ) with the result that the only eukaryotic promoter elements they contained were those of the human apo-AII gene. This series of plasmids was transfected into logarithmically growing cultures of HeLa, Hep-3B, Hep-G2 and CaCo-2 cells. As a negative control the religated vector plasmid containing no apo-AII sequences, but otherwise identical to the deletion series, was also transfected Into these cells. All the recombinants were co-transfected with an equal quantity of a plasmid (pH(35'SVBglH) containing a functional copy of the human B-globin gene, the transcription of which served as a measure of transfection efficiency. This plasmid contains the SV40 origin of replication and also expresses SV40 large T-antigen and so has the necessary machinery to replicate. The al-globin containing plasmids do not contain the SV40 origin of replication and therefore are not influenced by the presence of large T-antigen. pH05'SVBgin is the human equivalent of the rabbit globin construct p05'SVBglII described by Grosveld et al [52] .
Total RNA was extracted 48 hrs after transfection and analysed by Northernblotting (see Fig.2 ) and quantitative densitometry. This indicated that paAII/5'1171 and 912, which contain respectively 1171 and 912 bp of apo-AII gene 5'-flanking DNA, are the only plasmids from which significant amounts of al-globln sequences are transcribed. The size of these al-globin containing transcripts is consistent with their expression being under the control of the normal apo-AII promoter and their pattern of . The same cells were also cotransfected with pH05'SVBglII. Total RNA was extracted from the cells 48 hrs later and 35 |ig analysed on each of two Northern blots following electrophoresis through formaldehyde containing 1.2% agarose gels. RNA extracted from cells which had either not been transfected (UT) or tranafected only with pH05'SVBglII (0) was similarly analysed. The RNA on one of the duplicate blots was hybridized to an al-globin specific probe while the other was hybridized to a probe specific for 0-globin. The al-globin probe was a nick-translated BstEII/PstI fragment isolated from pSValFd (Fig.l) . The 0-globln probe was a nick-translated AccI/EcoRl fragment isolated from pH05'SVBglII (see [94J. The position of the mature apoAn/al-globin transcript is arrowed. Autoradiography was performed at -70°C using an intensifying screen and preflashed Kodak X-O-mat S film. Exposures were on average 5 days. (Fig.l) . The bars on the left represent the additional apo-AII gene fragments introduced into potAII/5'210 in order to try and rescue its transcriptional activity. These fragments were all introduced in their correct orientation relative to the apo-AII sequences already present. However the Hindlll/Bglll fragment was also introduced in the reverse orientation, as indicated by the arrowhead. Negative numbers indicate the region of apo-AII 5' flanking sequence present in each fragment as measured from the transcription initiation site [31] . (C) Schematic restriction map of the expression vector pSalFd [34] indicating where the apo-AII gene fragments were inserted (see Fig.l for conventions used).
processing being as predicted (Fig.ID) . paAII/5'675, 210 and 117, which contain 675, 210 and 117 bp of 5' flanking DNA respectively, do not produce detectable quantities of transcripts containing al-globin. The production of ol-globin sequences by paAII/5'1171 and 912 is specific for the apo-AII producing cell lines Hep-3B, Hep-G2 and CaCo-2. This suggests that the 5' boundary of sequences required for the tissuespecific expression of apo-AII in both liver and Intestine lies between 912 and 675 bp upstream of the transcriptional start site of the gene.
It is difficult to rigorously exclude differential mRNA stability as contributing to these results. However this cannot account for the loss of activity following deletion of 5' flanking sequences since identical transcripts are involved. Therefore, it seems likely that these results reflect different rates of transcription initiation.
Determination of the approximate 3' border of sequences involved In the tissuespecific expression of the apo-AH gene
The construction of the plasmids employed in the identification of the approximate 3' boundary of the sequences identified above which are involved in the tissue-specific expression of apo-AII is described in Figure 3 .
The series of constructs generated were based on paAII/5'210 which had been previously shown to be non-functional (see Fig.2 ). Increasing amounts of additional apo-AII 5' flanking sequences to those already present were introduced into this pla8mid in an attempt to rescue its tissue-specific transcriptional activity. These plasmids were transfected into HeLa, Hep-3B, Hep-G2 and CaCo-2 cells as described previously. The parent plasmid, paAII/5'210, was transfected separately into each cell line as a negative control and all the constructs were co-transfected with pH35'SVBglII in order to control for transfection efficiency. Total RNA was extracted 48 hrs after transfection and analysed by Northern blotting (see Fig.4 ) and quantitative densitometry. These results demonstrate that paAII/5'210/5'383-912 and 383-912R are the only plasmids from which al-globin sequences are efficiently transcribed. However paAII/5'210/5791-912 appears to retain some transcriptional activity although this is only a fifth of that of paAII/5'210/5'383-912 and 383-912R. paAII/5'210/5'857-912, on the other hand, falls to produce a detectable level of transcripts containing al-globin. The transcriptional activity of aAII/5'210/5'383-912 is the same as that of 383-912R and both are specific for the apo-AII producing cell lines Hep-3B, Hep-G2 and CaCo-2. paAII/5'210/5'383-912 was subsequently al3O transfected into the embryonic fibroblast line DS-1 and the bladder carcinoma line EJ138. These two human cell lines do not produce apo-AII and, like HeLa cells, failed to express the hybrid gene which was introduced into them (data not shown). 
383-912R (383-912R
). The same cells were also co-transfected with pHB5'SVBglII. Total RNA was extracted from these cells and analysed by Northern blotting as described previously (Fig.2) . Only the duplicate filter hybridized with the al-globin probe is presented. The positions of the 28S and 18S ribosomal RNA species are Indicated. These RNAs are 6333 and 2366 nucleotides long respectively [95] . A similar pattern of hybridization was obtained when RNA extracted from transfected Hep-3B and CaCo-2 cells was analysed. However, RNA extracted from transfected HeLa cells gave no hybridization signal as did that extracted from EJ138 and DS-1 cells transfected with paAII/5'210/5'383-912 (see Fig.2 
for experimental details and conventions used).
The results presented in Figures 2 and A , when combined, implicate the 116 bp of 5' flanking sequence lying between 675 and 791 bp upstream of the transcription initiation site in the direction of the tissue-specific expression of the apo-AII gene (see Fig.5 ). In addition, the 121 bp immediately 5' of this region directs tissue-specific transcription at approximately 20% of the maximum observed level (Fig.4) . It is possible therefore that the upstream cis-acting regulatory sequences involved in the specificity of apo-AII gene expression span both of these regions. The activity of these sequences, like that of viral and cellular enhancers, appears to be orientation [34] indicating where the apo-AII gene fragments were inserted (see Fig.l for conventions used) .
independent [53] [54] [55] [56] [57] [58] [59] . Thus the cell-specific transcription of apo-II In both liver and intestine appears to be controlled, at least in part, by one or more "enhancer-like" elements. The same cells were also cotransfected with pHS5'SVBglH. Total RNA was extracted and analysed as described in Figure 2 . Only the duplicate filter hybridized with the alglobin probe is presented. A similar pattern of hybridization was obtained when RNA extracted from transfected Hep-G2 and CaCo-2 cells was analysed. However, RNA extracted from transfected HeLa cells gave no hybridization signal (see Fig.2 for experimental details and conventions used).
region was used in isolation to try and rescue the tissue specific transcrlptional activity of paAII/5710. This seguence is contained within a 140 bp Hinfl/Alul fragment which was introduced into p aAn/5*210 exactly as the fragments described previously (see Flg.5). Two constructs were generated, paAII/5'210/5'653-793 contained the Hinfl/Alul restriction fragment in its correct orientation relative to the 5' flanking sequences already present in the parent plasmid vector, while in paAU/5'210/5'653-793R it was inserted in the reverse orientation. These two plasmids were transfected separately into HeLa, Hep-3B, Hep-G2 and CaCo-2 cells as before. The parent plasmid, p aAII/5'210, was again included as a negative control and all three constructs were co-transfected with pH05'SVBglII.
Transcripts were analysed by Northern blotting (Fig.6 ) and quantitative densitometry. This indicated that both orientations of the Hinfl/Alul fragment could rescue, to the same extent, the tissue-specific expression of paAII/5'210. However although the Hinfl/Alul fragment retains the enhancer properties of the Hindlll/Bglll fragment, it, like the Hindlll/Hinfl fragment immediately upstream (Fig.4) , confers only a fifth of the transcriptional activity directed by the larger fragment (Fig.4 cf  Fig.6 ).
The pattern of expression of all the deletion constructs analysed appears identical in all three apo-AII producing cell lines. Consequently in both liver and intestine the same DNA sequence seems to be important in causing the expression of the apo-AII gene. The relatively low enhancer activity of the Hinfl/Alul fragment indicates that it does not contain all this regulatory DNA sequence. The remainder may reside immediately upstream in the Hindlll/Hinfl fragment (Fig.3) as these sequences aUo appear to confer a low level of tissue-3pecific expression on the apo-AII gene (Fig.4) . Therefore this regulatory sequence probably lies in the 259 bp between the Hindlll and Alul restriction recognition sites, 912 and 653 bp upstream, respectively of the apo-AII transcription initiation point (Figs. 5 and 8) .
Evidence that the apo-AII enhancer confers cell-specific expression on the apo-AII gene
The sequences between 912 and 653 bp upstream of the transcription initiation site have been shown to have enhancer properties and to be involved in the tissuespecific expression of apo-AII. However this has always been in conjunction with the apo-AII sequences present in paAn/5'210. Therefore it could be possible that the apo-AII "enhancer", like those linked to the imrnunoglobulin and insulin genes [1] [2] is associated with elements in the promoter region which also exhibit a pronounced host cell preference. Therefore, in order to determine whether paAII/S^lO contained sequences that could independently direct tissue specific expression, its transcriptional activity was rescued not by the apo-AII "enhancer", but by the non-specific SV40 enhancer. This and other viral enhancers have been shown to be incapable of overriding the specificity of expression associated with a number of cellular genes [1] [2] .
A StuI/EcoRl fragment isolated from pSValFd (Fig.l) containing the SV40 enhancer and origin was cloned into paAII/5'210 in exactly the same position upstream of the apoAIl promoter as was the apo-AII "enhancer-like" element (Figs.3 and 5) . The resulting construct, potAII/571O/SV4O, was then transfected into HeLa and Hep-3B cells. The parent plasmid, paAII/5'210, was introduced separately as a negative control and both constructs were cotransfected with pHB5'SVBglII to check for variations in transfection efficiency. Total RNA was extracted and analysed by Northern blotting (Fig.7) and quantitative densitometry. This indicated that the SV40 enhancer causes that part of the apo-AIl gene present in paAIl/5'210 to be expressed both in HeLa and in Hep-3B cells. Therefore, while the apo-AIl enhancer rescues expression In a tissue specific manner, the SV40 enhancer rescues expression non8peclflcally. Thus the apo-AIl gene, stretching from 210 bp upstream to 1168 bp downstream of the transcription start site, appears to contain no elements that can independently direct tissue specific expression. Rather, it is the apo-AIl enhancer centred at 782 bp upstream that confers such specificity, either independently or in conjunction with other apo-AIl sequences. In addition, the presence of apo-AIl/alglobin hybrid transcripts in HeLa cells discounts tha possibility that mRNA instability accounted for the results previously obtained with these cells (Fig.2) . 
DISCUSSION
The introduction of a series of deletion and substitution mutants of the apo-AH gene into human cells In culture has allowed the identification of a cellular "enhancerlike" element upstream of the transcription initiation site. The "enhancer" appears to be absolutely required for tissue specific transcription from the apo-AH promoter, directing expression both in liver and intestine derived cells but not in bladder, fibroblast or cervical epithelial cell lines. Two other examples of dual tissue-specific expression have been similarly studied, one in Drosophila [60] [61] and one in man [8] . These reports demonstrated that while the expression of the human antithrombin III gene in both liver and kidney cells is directed by a single enhancer region of about 800 bp, different cis-acting regulatory regions appear to direct transcription of the Drosophila yolk protein I gene in fat body and ovarian follicle tissue.
In the case of some immunoglobulin genes [2, [62] [63] [64] [65] and the rat insulin gene [1] , it has been demonstrated that promoter sequences display cell-type specificity independently of their associated enhancers. The human apo-AII promoter region, like those of the chicken lysozyme [4] and o-crystallin [66] genes, does not exhibit this type of specificity in the cells used in these transient expression studies. Rather, the replacement of the apo-AII enhancer with that of SV4O leads to comparable expression from the apo-AII promoter both in apo-AII producing Hep-3B and non-producing HeLa cells.
The human apo-AII "enhancer-like" element contains none of the consensus sequence motifs which have been previously identified in cellular enhancers [67] [68] [69] [70] However, the minimal apo-AII enhancer fragment (-653 to -912) identified in this study does contain the sequence 5'-ATCAAAT-3' (Fig.8) . This is very similar to the highly conserved octanucleotide 5'-ATGCAAAT-3' ("cd-element") found upstream of the Immunoglobulin heavy chain promoter and, in the reverse orientation, within the heavy chain enhancer and upstream of the kappa-light chain promoter [71] . In all three locations this sequence has been implicated in tissue specific expression [2, [62] [63] [64] [65] 72] and appears to bind both lymphold specific and non-tissue-specific protein factors [68, 70, One nucleotide downstream of the "cd-like element", the enhancer region of apo-AII contains the sequence 5'-ACCAGGTGCC-3\ This is homologous to the consensus sequence, 5'-GCCAGGTGGC-3', of a group of related motifs which also appear to be involved in the activity of the immunoglobulin enhancers [67, 68, 70, 76] .
The other obvious structural feature of the apo-AII enhancer sequence is the presence of three pairs of inverted repeats, one at its 5 1 end and two at its 3' end (Flg.8).
Between the 3 1 IRs, the sequence 5'-TTCACCTCTTTTCC-3' contains homologies both with a viral enhancer consensus sequence [77] and with a region ("El") (Fig.9 ). Mutations within this region of the B-globin gene have been linked with B-thalassemia [79, 80] while a naturally occurring mutation within the homologous region of the human apo-AI gene has been implicated in hyperlipidernia [81] . The element within the apo-AI gene promoter represents one of a number of apolipoprotein gene sequences which share homologies with the apo-AII enhancer [Sharpe et al., in preparation] . This is not surprising since the apo-AII gene belongs to a well characterized gene family that is thought to have arisen from a common ancestor [33, [82] [83] [84] and whose expression might therefore conceivably involve common control mechanisms. Indeed when potential regulatory sequences of the apo-AII gene were compared to those of the other apolipoprotein genes [33, 85] , a region of common homology was found. In the apo-AII gene this lies between 469 bp and 495 bp upstream of the transcription initiation site. Consequently, In terms of the apo-AII gene deletions employed in this study, it was both absent from actively transcribed constructs and present in others which were non-functional. Therefore if this sequence is involved in some common aspect of the regulation of apolipoprotein gene expression, it appears either unable to act in isolation and/or is relevant to a process other than basic transcriptlonal competence. Further downstream from the region of common homology, 355 and 304 bp 5' of the CAP site of the gene, there are potential viral enhancer core sequences, 5'-CTTTCCA-3' [86] . These are unlikely to have any functional significance since they were absent from all the constructs in which the tissue-specific expression of the apo-AII gene was rescued.
While the functional importance of the various sequences within the apo-AII enhancer which we have discussed is unclear, it is interesting to note that when this region is divided into two parts, one containing the 5' pair of Inverted repeats and the other the "cd-like element" together with the two 3' pairs of inverted repeats, each retains only approximately 20% of the activity of the intact enhancer. Therefore it seems likely that this element has at minimum a bipartite structure, the components of which cooperate to give the apo-AII enhancer its full activity. The region of common homology, 495 bp upstream of the CAP site, may be Involved in this synergistic process.
The regulatory element identified in this study is clearly vital to the dual tissuespecific transcription of the human apo-AII gene. Mutations within it will therefore represent prime candidates for genetic lesions contributing to abnormal apo-II levels. These levels are of critical importance given that they appear to have a strong negative correlation with the prevalence of myocardial infarction [87] and peripheral vascular disease [88] , A number of apolipoprotein gene RFLPs have been found associated with abnormalities within the lipid transport system [22, 23, [89] [90] [91] [92] . Scott et al [25] have identified such a polymorphism of the apo-AII gene that is linked both to high plasma apo-AII levels and altered HDL composition. Moreover, in inbred strains of mice, a locus tightly linked to the apo-AII gene has been shown to confer resistance to diet induced hyperlipidemia and atherosclerosis [93] . In all these studies the proteins involved appear normal, indicating the causative lesions may lie in regulatory regions such as the apo-AII enhancer.
